Development of topical methima-zole to treat skin hyperpigmented lesions

Scientis Pharma SA

Incorporated

03.12.2010

Headquarters

Genève

Support

Skin hyperpigmented lesions (mark of pregnancy, lenigos, post acne hyperpigmented scars etc.) are very frequent dermatologic problems. Such prob-lems have been treated since many years by creams containing hydroquinone as the active substance. Hydroquinone has been recently banned by FDA and European authorities since it has been identified as a toxic and carcinogenic compound. Methimazole is an FDA-approved oral medication used for the treatment of hyperthyroid-ism. We have shown, for the first time, that if methimazole is made into a cream (topical 5% methimazole) it removes the skin hyperpigmented lesions after 4-6 weeks of application in human.